Jacobs Levy Equity Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$25.2M |
| 2 |
Ashland
ASH
|
+$17.2M |
| 3 |
IBM
IBM
|
+$17.1M |
| 4 |
Madison Square Garden
MSGS
|
+$16.7M |
| 5 |
Valero Energy
VLO
|
+$16.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CVS Health
CVS
|
+$35.9M |
| 2 |
Qualcomm
QCOM
|
+$29M |
| 3 |
BCR
CR Bard Inc.
BCR
|
+$27.5M |
| 4 |
Agilent Technologies
A
|
+$26.4M |
| 5 |
Northrop Grumman
NOC
|
+$25.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.21% |
| 2 | Financials | 19.14% |
| 3 | Healthcare | 11.97% |
| 4 | Industrials | 11.47% |
| 5 | Consumer Discretionary | 10.84% |
Similar funds
Jacobs Levy Equity Management's Q2 2017 Portfolio in Review
As of Q2 2017, Jacobs Levy Equity Management held 1,103 positions worth $4.68B, down 5.5% from $4.95B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Jacobs Levy Equity Management withdrew a net $364M in Q2 2017, closing 187 positions and reducing 317 holdings. Its most notable exit was CVS Health, an estimated $35.9M position sold in full.
By sector, the portfolio is most concentrated in Technology at 19% of assets, down from 20% a quarter earlier, followed by Financials and Healthcare.
Against the trend, Jacobs Levy Equity Management opened a new position in Humana worth $26.8M.
- Jacobs Levy Equity Management's largest Q2 2017 buy was Humana: 111,320 shares worth $26.8M.
- Jacobs Levy Equity Management added most to Madison Square Garden in Q2 2017, an estimated $16.7M increase.
- Jacobs Levy Equity Management's biggest Q2 2017 reduction was Agilent Technologies, cutting an estimated $26.4M.
- Jacobs Levy Equity Management fully exited CVS Health in Q2 2017, selling an estimated $35.9M.
- Jacobs Levy Equity Management's ten largest holdings make up 11% of its $4.68B portfolio in Q2 2017.
- Jacobs Levy Equity Management opened 193 new positions and closed 187 in Q2 2017.
- Jacobs Levy Equity Management's portfolio value fell 5.5% quarter-over-quarter to $4.68B.
Based on Jacobs Levy Equity Management's 13F filing for Q2 2017, filed 14 Aug 2017.